中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肠道微生态与自身免疫性肝炎发生发展的关系

夏雨艳 曾琼戎 李福建 黎凤炎 李琪 唐利瑕 张国

引用本文:
Citation:

肠道微生态与自身免疫性肝炎发生发展的关系

DOI: 10.12449/JCH240225
基金项目: 

广西科技计划项目 (AD17129027);

广西壮族自治区卫生健康委员会重点(培育)实验室 (ZZH2020006)

利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:夏雨艳负责查阅文献,起草论文;黎凤炎、李琪、唐利瑕参与部分内容撰写;张国、李福建、曾琼戎拟定写作思路,指导和修改论文,核对有关文献并最后定稿。
详细信息
    通信作者:

    张国, zhangguogx@hotmail.com (ORCID: 0000-0001-7755-443X)

Association of intestinal microecology with the development and progression of autoimmune hepatitis

Research funding: 

Guangxi Science and Technology Program Project (AD17129027);

Key (Cultivation) Laboratory of Health Commission of Guangxi Zhuang Autonomous Region (ZZH2020006)

More Information
  • 摘要: 自身免疫性肝炎(AIH)是以慢性肝脏炎症为特点的自身免疫性疾病,发病率逐年升高,社会医疗负担不容小视。肠道微生态正成为自身免疫性疾病研究的热点。近年来认为肠道微生态的改变会引起自身免疫状态、菌群代谢产物和肠道屏障的改变,是AIH发病的驱动因素之一。早期诊断和正确的治疗有助于改善AIH患者的预后。本文介绍了AIH患者肠道菌群的特点、肠道微生态失衡对AIH发病机制的影响以及从肠道微生态角度出发简述了相关治疗方案,旨在全面理解和解释肠道微生态在AIH中的作用,了解肠道微生态平衡对AIH致病机制、诊断和治疗的影响。

     

  • [1] Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of autoimmune hepatitis(2021)[J]. J Clin Hepatol, 2022, 38( 1): 42- 49. DOI: 10.3969/j.issn.1001-5256.2022.01.008.

    中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38( 1): 42- 49. DOI: 10.3969/j.issn.1001-5256.2022.01.008.
    [2] PUUSTINEN L, BARNER-RASMUSSEN N, PUKKALA E, et al. Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: A nationwide register-based cohort study in Finland[J]. Dig Liver Dis, 2019, 51( 9): 1294- 1299. DOI: 10.1016/j.dld.2019.01.015.
    [3] GRØNBAEK L, OTETE H, BAN L, et al. Incidence, prevalence and mortality of autoimmune hepatitis in England 1997-2015. A population-based cohort study[J]. Liver Int, 2020, 40( 7): 1634- 1644. DOI: 10.1111/liv.14480.
    [4] LAMBA M, NGU JH, STEDMAN CAM. Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2021, 19( 3): 573- 579. DOI: 10.1016/j.cgh.2020.05.061.
    [5] TRIVEDI PJ, HIRSCHFIELD GM. Recent advances in clinical practice: Epidemiology of autoimmune liver diseases[J]. Gut, 2021, 70( 10): 1989- 2003. DOI: 10.1136/gutjnl-2020-322362.
    [6] FLOREANI A, RESTREPO-JIMÉNEZ P, SECCHI MF, et al. Etiopathogenesis of autoimmune hepatitis[J]. J Autoimmun, 2018, 95: 133- 143. DOI: 10.1016/j.jaut.2018.10.020.
    [7] TORRES J, HU JZ, SEKI A, et al. Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice[J]. Gut, 2020, 69( 1): 42- 51. DOI: 10.1136/gutjnl-2018-317855.
    [8] NABHANI Z AL, EBERL G. Imprinting of the immune system by the microbiota early in life[J]. Mucosal Immunol, 2020, 13( 2): 183- 189. DOI: 10.1038/s41385-020-0257-y.
    [9] BOULUND U, BASTOS DM, FERWERDA B, et al. Gut microbiome associations with host genotype vary across ethnicities and potentially influence cardiometabolic traits[J]. Cell Host Microbe, 2022, 30( 10): 1464- 1480. DOI: 10.1016/j.chom.2022.08.013.
    [10] LEE BT, TANA MM, KAHN JA, et al. We are not immune: Racial and ethnic disparities in autoimmune liver diseases[J]. Hepatology, 2021, 74( 5): 2876- 2887. DOI: 10.1002/hep.31985.
    [11] LYNCH SV, PEDERSEN O. The human intestinal microbiome in health and disease[J]. N Engl J Med, 2016, 375( 24): 2369- 2379. DOI: 10.1056/NEJMra1600266.
    [12] TERZIROLI BERETTA-PICCOLI B, MIELI-VERGANI G, VERGANI D. Autoimmmune hepatitis[J]. Cell Mol Immunol, 2022, 19( 2): 158- 176. DOI: 10.1038/s41423-021-00768-8.
    [13] WEI YR, LI YM, YAN L, et al. Alterations of gut microbiome in autoimmune hepatitis[J]. Gut, 2020, 69( 3): 569- 577. DOI: 10.1136/gutjnl-2018-317836.
    [14] LOU JM, JIANG Y, RAO BC, et al. Fecal microbiomes distinguish patients with autoimmune hepatitis from healthy individuals[J]. Front Cell Infect Microbiol, 2020, 10: 342. DOI: 10.3389/fcimb.2020.00342.
    [15] LIWINSKI T, CASAR C, RUEHLEMANN MC, et al. A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis[J]. Aliment Pharmacol Ther, 2020, 51( 12): 1417- 1428. DOI: 10.1111/apt.15754.
    [16] WANG H, BANERJEE N, LIANG YJ, et al. Gut microbiome-host interactions in driving environmental pollutant trichloroethene-mediated autoimmunity[J]. Toxicol Appl Pharmacol, 2021, 424: 115597. DOI: 10.1016/j.taap.2021.115597.
    [17] WANG H, WANG Q, YANG CM, et al. Bacteroides acidifaciens in the gut plays a protective role against CD95-mediated liver injury[J]. Gut Microbes, 2022, 14( 1): 2027853. DOI: 10.1080/19490976.2022.2027853.
    [18] CHEN JN, LI XH, ZENG P, et al. Lamina propria interleukin 17 A aggravates natural killer T-cell activation in autoimmune hepatitis[J]. FASEB J, 2022, 36( 6): e22346. DOI: 10.1096/fj.202101734RRR.
    [19] CENTA M, WEINSTEIN EG, CLEMENTE JC, et al. Impaired central tolerance induces changes in the gut microbiota that exacerbate autoimmune hepatitis[J]. J Autoimmun, 2022, 128: 102808. DOI: 10.1016/j.jaut.2022.102808.
    [20] DALILE B, VAN OUDENHOVE L, VERVLIET B, et al. The role of short-chain fatty acids in microbiota-gut-brain communication[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 8): 461- 478. DOI: 10.1038/s41575-019-0157-3.
    [21] LIU QQ, TIAN HX, KANG YB, et al. Probiotics alleviate autoimmune hepatitis in mice through modulation of gut microbiota and intestinal permeability[J]. J Nutr Biochem, 2021, 98: 108863. DOI: 10.1016/j.jnutbio.2021.108863.
    [22] ZHANG HX, LIU M, LIU X, et al. Bifidobacterium animalis ssp. lactis 420 mitigates autoimmune hepatitis through regulating intestinal barrier and liver immune cells[J]. Front Immunol, 2020, 11: 569104. DOI: 10.3389/fimmu.2020.569104.
    [23] BHASKARAN N, QUIGLEY C, PAW C, et al. Role of short chain fatty acids in controlling T(regs) and immunopathology during mucosal infection[J]. Front Microbiol, 2018, 9: 1995. DOI: 10.3389/fmicb.2018.01995.
    [24] HU ED, CHEN DZ, WU JL, et al. High fiber dietary and sodium butyrate attenuate experimental autoimmune hepatitis through regulation of immune regulatory cells and intestinal barrier[J]. Cell Immunol, 2018, 328: 24- 32. DOI: 10.1016/j.cellimm.2018.03.003.
    [25] WU JL, ZOU JY, HU ED, et al. Sodium butyrate ameliorates S100/FCA-induced autoimmune hepatitis through regulation of intestinal tight junction and toll-like receptor 4 signaling pathway[J]. Immunol Lett, 2017, 190: 169- 176. DOI: 10.1016/j.imlet.2017.08.005.
    [26] YANG JS, XIE WT, YU KK, et al. Methyl butyrate attenuates concanavalin A-induced autoimmune hepatitis by inhibiting Th1-cell activation and homing to the liver[J]. Cell Immunol, 2022, 378: 104575. DOI: 10.1016/j.cellimm.2022.104575.
    [27] ELSHERBINY NM, RAMMADAN M, HASSAN EA, et al. Autoimmune hepatitis: Shifts in gut microbiota and metabolic pathways among Egyptian patients[J]. Microorganisms, 2020, 8( 7): 1011. DOI: 10.3390/microorganisms8071011.
    [28] MA JL, HONG Y, ZHENG NN, et al. Gut microbiota remodeling reverses aging-associated inflammation and dysregulation of systemic bile acid homeostasis in mice sex-specifically[J]. Gut Microbes, 2020, 11( 5): 1450- 1474. DOI: 10.1080/19490976.2020.1763770.
    [29] MENCARELLI A, RENGA B, MIGLIORATI M, et al. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis[J]. J Immunol, 2009, 183( 10): 6657- 6666. DOI: 10.4049/jimmunol.0901347.
    [30] ZHANG T, RAO QR, DAI MY, et al. Tripterygium wilfordii protects against an animal model of autoimmune hepatitis[J]. J Ethnopharmacol, 2023, 309: 116365. DOI: 10.1016/j.jep.2023.116365.
    [31] LARABI AB, MASSON HLP, BÄUMLER AJ. Bile acids as modulators of gut microbiota composition and function[J]. Gut Microbes, 2023, 15( 1): 2172671. DOI: 10.1080/19490976.2023.2172671.
    [32] FUNG TC, VUONG HE, LUNA CDG, et al. Intestinal serotonin and fluoxetine exposure modulate bacterial colonization in the gut[J]. Nat Microbiol, 2019, 4( 12): 2064- 2073. DOI: 10.1038/s41564-019-0540-4.
    [33] ALMISHRI W, SHAHEEN AA, SHARKEY KA, et al. The antidepressant mirtazapine inhibits hepatic innate immune networks to attenuate immune-mediated liver injury in mice[J]. Front Immunol, 2019, 10: 803. DOI: 10.3389/fimmu.2019.00803.
    [34] XUE RF, ZHANG HM, PAN J, et al. Peripheral dopamine controlled by gut microbes inhibits invariant natural killer T cell-mediated hepatitis[J]. Front Immunol, 2018, 9: 2398. DOI: 10.3389/fimmu.2018.02398.
    [35] ZHANG HX, LIU M, ZHONG WL, et al. Leaky gut driven by dysbiosis augments activation and accumulation of liver macrophages via RIP3 signaling pathway in autoimmune hepatitis[J]. Front Immunol, 2021, 12: 624360. DOI: 10.3389/fimmu.2021.624360.
    [36] LIN HW, LIN J, PAN TT, et al. Polymeric immunoglobulin receptor deficiency exacerbates autoimmune hepatitis by inducing intestinal dysbiosis and barrier dysfunction[J]. Cell Death Dis, 2023, 14( 1): 68. DOI: 10.1038/s41419-023-05589-3.
    [37] LIN R, ZHOU L, ZHANG J, et al. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis[J]. Int J Clin Exp Pathol, 2015, 8( 5): 5153- 5160.
    [38] MA L, ZHANG LW, ZHUANG Y, et al. Lactobacillus improves the effects of prednisone on autoimmune hepatitis via gut microbiota-mediated follicular helper T cells[J]. Cell Commun Signal, 2022, 20( 1): 83. DOI: 10.1186/s12964-021-00819-7.
    [39] KANG YB, KUANG XY, YAN H, et al. A novel synbiotic alleviates autoimmune hepatitis by modulating the gut microbiota-liver axis and inhibiting the hepatic TLR4/NF-‍κB/NLRP3 signaling pathway[J]. mSystems, 2023, 8( 2): e0112722. DOI: 10.1128/msystems.01127-22.
    [40] MA L, ZHANG LW, SONG JG, et al. Fecal microbiota transplantation controls progression of experimental autoimmune hepatitis in mice by modulating the TFR/TFH immune imbalance and intestinal microbiota composition[J]. Front Immunol, 2021, 12: 728723. DOI: 10.3389/fimmu.2021.728723.
    [41] MANRIQUE P, DILLS M, YOUNG MJ. The human gut phage community and its implications for health and disease[J]. Viruses, 2017, 9( 6): 141. DOI: 10.3390/v9060141.
    [42] TOMOFUJI Y, KISHIKAWA T, MAEDA Y, et al. Whole gut virome analysis of 476 Japanese revealed a link between phage and autoimmune disease[J]. Ann Rheum Dis, 2022, 81( 2): 278- 288. DOI: 10.1136/annrheumdis-2021-221267.
    [43] SCALDAFERRI F, LOPETUSO LR, PETITO V, et al. Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for‘gut barrier protectors’ in IBD?[J]. United European Gastroenterol J, 2014, 2( 2): 113- 122. DOI: 10.1177/2050640614520867.
    [44] WU HM, WEI J, WANG K, et al. Mucus protectors: Promising therapeutic strategies for inflammatory bowel disease[J]. Med Hypotheses, 2018, 120: 55- 59. DOI: 10.1016/j.mehy.2018.08.013.
    [45] QUE W, LIN H, LI X, et al. Koumine ameliorates concanavalin A-induced autoimmune hepatitis in mice: involvement of the Nrf2, NF-κB pathways, and gut microbiota[J]. Int Immunopharmacol, 2023, 114: 109573. DOI: 10.1016/j.intimp.2022.109573.
  • 加载中
计量
  • 文章访问数:  340
  • HTML全文浏览量:  102
  • PDF下载量:  64
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-06-20
  • 录用日期:  2023-07-11
  • 出版日期:  2024-02-19
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回